Suppr超能文献

在 Ziabetus(2 型糖尿病)中的疗效:一项单盲随机对照试验。

Efficacy of in Ziabetus (type 2 Diabetes Mellitus): a single blind randomized controlled trial.

机构信息

Department of Moalajat, Sufiya Unani Medical College Hospital and Research Centre, Bara Chakia East Champaran, Bihar, India.

Department of Moalajat, National Institute of Unani Medicine, Bangalore, India.

出版信息

J Complement Integr Med. 2020 Jun 18;18(1):147-153. doi: 10.1515/jcim-2020-0072.

Abstract

BACKGROUND AND OBJECTIVES

Diabetes is a serious threat to global health that respects neither socioeconomic status nor national boundaries. Globally, diabetes is among the top 10 causes of death. Unani system argued the effectiveness of several anti-hyperglycemic drugs, and all such drugs looked-for to be validated on scientifically. Hence a clinical trial was contemplated to evaluate the clinical efficacy of in the management of Diabetes Mellitus.

METHODS

This study was conducted as single blind randomized control, on 40 patients of type 2 diabetes with the test (n=20) and control (n=20) groups for 45 days. Test group received at the dose of three Qurs twice a day, and control group received two capsules Diabeat twice a day before meal. Subjective (at 0, 15th, 30th, and 45th) and objective parameters were assessed as pre-post treatment respectively.

RESULTS

After treatment with test compound significant reduction was observed in all the subjective parameters viz. polyuria, polydipsia, polyphagia and tiredness in comparison of control group. The objective parameters FBS and PPBS was found to be significantly reduced (p<0.001) in both the groups where as HbA1c was found unchanged in test group but control drug showed highly significant reduction in HbA1c (p<0.001).The results were assessed statistically using two tailed Student's -test, and Fischer exact test.

CONCLUSION

On the basis of above observation it is concluded that the test compound has significant anti-diabetic effect which is evidentially observed both in subjective and objective parameters in test group in comparison of control group ().

摘要

背景和目的

糖尿病是一种严重威胁全球健康的疾病,它不分社会经济地位或国界。在全球范围内,糖尿病是十大死因之一。顺势疗法系统认为几种降血糖药物是有效的,所有这些药物都需要在科学上得到验证。因此,考虑进行一项临床试验,以评估 在糖尿病管理中的临床疗效。

方法

这项研究是单盲随机对照试验,共纳入 40 名 2 型糖尿病患者,分为试验组(n=20)和对照组(n=20),治疗期为 45 天。试验组给予 ,剂量为每日三次 Qurs,对照组给予 ,剂量为每日两次餐前服用 Diabeat。分别在治疗前和治疗后评估主观(第 0、15、30 和 45 天)和客观参数。

结果

与对照组相比,试验组在所有主观参数(多尿、多饮、多食和疲劳)方面均观察到显著改善。空腹血糖(FBS)和餐后血糖(PPBS)在两组均显著降低(p<0.001),而试验组的糖化血红蛋白(HbA1c)无变化,但对照组的 HbA1c 显著降低(p<0.001)。采用双尾学生 t 检验和 Fischer 确切检验对结果进行统计学评估。

结论

根据上述观察结果,可得出结论,试验化合物 具有显著的抗糖尿病作用,在试验组中,无论是主观参数还是客观参数,均明显优于对照组()。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验